Skip to main content
NCBI home page
Gut logoLink to Gut
. 2001 Mar;48(3):378–383. doi: 10.1136/gut.48.3.378

Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C

B Wesche 1, E Jaeckel 1, C Trautwein 1, H Wedemeyer 1, A Falorni 1, H Frank 1, A von zur Muhlen 1, M Manns 1, G Brabant 1
PMCID: PMC1760154  PMID: 11171829

Abstract

BACKGROUND/AIMS—Interferon alpha (IFN-α) therapy for chronic hepatitis C may trigger induction of autoimmunity against several organs. Immune reactions against distinct adrenocortical protein antigens involved in adrenal autoimmune disease have not been reported to date. Therefore, we investigated the development of highly sensitive and specific adrenal autoantibodies in patients with chronic hepatitis C in response to IFN-α treatment. In addition, we studied induction of pancreatic islet and thyroid autoantibodies.
PATIENTS/METHODS—Sera of 75 patients (42 males, 33 females; mean age 47 (13) years) were analysed before, during, and after IFN-α therapy (9-18×106 IE/week; mean duration 8.3 (3.5) months). Autoantibodies (Abs) to adrenal 21-hydroxylase (21OH-Abs), and to islet glutamic acid decarboxylase (GAD65-Abs) and protein tyrosine phosphatase (IA2-Abs) were determined by a radiobinding assay using 35S labelled protein generated by an in vitro translation system. Thyroid antibodies were measured by a commercially available ELISA.
RESULTS—Thirteen of 75 patients were initially positive for some of the autoantibodies. During or after IFN-α therapy, 3/62 initially negative patients (4.8%) developed 21OH-Abs. GAD65-Abs or IA2-Abs appeared in 5/62 and 1/62 patients, respectively (9.7% in total). In 12/62 patients (19.4%), thyroid specific antibodies appeared. In none of the 21OH-Ab positive subjects was adrenal dysfunction observed, and no patient with islet autoantibodies developed diabetes mellitus or impaired glucose tolerance.
CONCLUSIONS—IFN-α induces 21OH-Abs in some cases, while islet and thyroid specific autoantibodies are more frequently found. However, our results indicate for the first time that the adrenal cortex also has to be considered as a potential target of IFN-α related autoimmunity.


Keywords: hepatitis C; interferon alpha; autoantibodies; adrenal cortex; pancreatic islet cells

Full Text

The Full Text of this article is available as a PDF (151.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abiru N., Takino H., Yano M., Kawasaki E., Yamasaki H., Yamaguchi Y., Akazawa S., Nagataki S. Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J Autoimmun. 1996 Oct;9(5):683–688. doi: 10.1006/jaut.1996.0089. [DOI] [PubMed] [Google Scholar]
  2. Alvarez F., Berg P. A., Bianchi F. B., Bianchi L., Burroughs A. K., Cancado E. L., Chapman R. W., Cooksley W. G., Czaja A. J., Desmet V. J. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929–938. doi: 10.1016/s0168-8278(99)80297-9. [DOI] [PubMed] [Google Scholar]
  3. Atkinson M. A., Maclaren N. K. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994 Nov 24;331(21):1428–1436. doi: 10.1056/NEJM199411243312107. [DOI] [PubMed] [Google Scholar]
  4. Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Le Floch J. P., Lemmonier C., Benhamou J. P., Bok B. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993 Dec;39(6):657–661. doi: 10.1111/j.1365-2265.1993.tb02423.x. [DOI] [PubMed] [Google Scholar]
  5. Boadas J., Rodríguez-Espinosa J., Enríquez J., Miralles F., Martínez-Cerezo F. J., González P., Madoz P., Vilardell F. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol. 1995 Jun;22(6):611–615. doi: 10.1016/0168-8278(95)80216-9. [DOI] [PubMed] [Google Scholar]
  6. Bonifacio E., Genovese S., Braghi S., Bazzigaluppi E., Lampasona V., Bingley P. J., Rogge L., Pastore M. R., Bognetti E., Bottazzo G. F. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia. 1995 Jul;38(7):816–822. doi: 10.1007/s001250050358. [DOI] [PubMed] [Google Scholar]
  7. Campbell S., Mclaren E. H., Danesh B. J. Rapidly reversible increase in insulin requirement with interferon. BMJ. 1996 Jul 13;313(7049):92–92. doi: 10.1136/bmj.313.7049.92a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carella C., Amato G., Biondi B., Rotondi M., Morisco F., Tuccillo C., Chiuchiolo N., Signoriello G., Caporaso N., Lombardi G. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res. 1995;44(3):110–114. doi: 10.1159/000184606. [DOI] [PubMed] [Google Scholar]
  9. Chedin P., Cahen-Varsaux J., Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1996 Sep 15;125(6):521–521. doi: 10.7326/0003-4819-125-6-199609150-00035. [DOI] [PubMed] [Google Scholar]
  10. Choudhuri K., Gregorio G. V., Mieli-Vergani G., Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology. 1998 Nov;28(5):1177–1181. doi: 10.1002/hep.510280502. [DOI] [PubMed] [Google Scholar]
  11. Deutsch M., Dourakis S., Manesis E. K., Gioustozi A., Hess G., Horsch A., Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997 Jul;26(1):206–210. doi: 10.1002/hep.510260127. [DOI] [PubMed] [Google Scholar]
  12. Fabris P., Betterle C., Floreani A., Greggio N. A., de Lazzari F., Naccarato R., Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet. 1992 Aug 29;340(8818):548–548. doi: 10.1016/0140-6736(92)91744-s. [DOI] [PubMed] [Google Scholar]
  13. Fabris P., Betterle C., Greggio N. A., Zanchetta R., Bosi E., Biasin M. R., de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998 Mar;28(3):514–517. doi: 10.1016/s0168-8278(98)80328-0. [DOI] [PubMed] [Google Scholar]
  14. Falorni A., Laureti S., Nikoshkov A., Picchio M. L., Hallengren B., Vandewalle C. L., Gorus F. K., Tortoioli C., Luthman H., Brunetti P. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. Clin Exp Immunol. 1997 Feb;107(2):341–346. doi: 10.1111/j.1365-2249.1997.262-ce1153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Falorni A., Nikoshkov A., Laureti S., Grenbäck E., Hulting A. L., Casucci G., Santeusanio F., Brunetti P., Luthman H., Lernmark A. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab. 1995 Sep;80(9):2752–2755. doi: 10.1210/jcem.80.9.7673419. [DOI] [PubMed] [Google Scholar]
  16. Falorni A., Ortqvist E., Persson B., Lernmark A. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods. 1995 Oct 12;186(1):89–99. doi: 10.1016/0022-1759(95)00139-2. [DOI] [PubMed] [Google Scholar]
  17. Fattovich G., Betterle C., Brollo L., Pedini B., Giustina G., Realdi G., Alberti A., Ruol A. Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol. 1991 Jun;34(2):132–135. doi: 10.1002/jmv.1890340212. [DOI] [PubMed] [Google Scholar]
  18. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996 Jan;24(1):38–47. doi: 10.1016/s0168-8278(96)80184-x. [DOI] [PubMed] [Google Scholar]
  19. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., Vazquez R., Ocete E., Olea N., Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998 Jul 13;158(13):1445–1448. doi: 10.1001/archinte.158.13.1445. [DOI] [PubMed] [Google Scholar]
  20. Foulis A. K., Liddle C. N., Farquharson M. A., Richmond J. A., Weir R. S. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986 May;29(5):267–274. doi: 10.1007/BF00452061. [DOI] [PubMed] [Google Scholar]
  21. Gianani R., Rabin D. U., Verge C. F., Yu L., Babu S. R., Pietropaolo M., Eisenbarth G. S. ICA512 autoantibody radioassay. Diabetes. 1995 Nov;44(11):1340–1344. doi: 10.2337/diab.44.11.1340. [DOI] [PubMed] [Google Scholar]
  22. Gorus F. K., Goubert P., Semakula C., Vandewalle C. L., De Schepper J., Scheen A., Christie M. R., Pipeleers D. G. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia. 1997 Jan;40(1):95–99. doi: 10.1007/s001250050648. [DOI] [PubMed] [Google Scholar]
  23. Gottsäter A., Landin-Olsson M., Fernlund P., Lernmark A., Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care. 1993 Jun;16(6):902–910. doi: 10.2337/diacare.16.6.902. [DOI] [PubMed] [Google Scholar]
  24. Hiéronimus S., Fredenrich A., Tran A., Benzaken S., Fénichel P. Antibodies to GAD in chronic hepatitis C patients. Diabetes Care. 1997 Jun;20(6):1044–1044. doi: 10.2337/diacare.20.6.1044a. [DOI] [PubMed] [Google Scholar]
  25. Imagawa A., Itoh N., Hanafusa T., Oda Y., Waguri M., Miyagawa J., Kono N., Kuwajima M., Matsuzawa Y. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1995 Mar;80(3):922–926. doi: 10.1210/jcem.80.3.7883851. [DOI] [PubMed] [Google Scholar]
  26. Imagawa A., Itoh N., Hanafusa T., Waguri M., Kuwajima M., Matsuzawa Y. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia. 1996 Jan;39(1):126–126. doi: 10.1007/BF00400426. [DOI] [PubMed] [Google Scholar]
  27. Imano E., Kanda T., Ishigami Y., Kubota M., Ikeda M., Matsuhisa M., Kawamori R., Yamasaki Y. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol. 1998 Feb;28(2):189–193. doi: 10.1016/0168-8278(88)80004-7. [DOI] [PubMed] [Google Scholar]
  28. Koh L. K., Greenspan F. S., Yeo P. P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997 Dec;7(6):891–896. doi: 10.1089/thy.1997.7.891. [DOI] [PubMed] [Google Scholar]
  29. Koivisto V. A., Pelkonen R., Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes. 1989 May;38(5):641–647. doi: 10.2337/diab.38.5.641. [DOI] [PubMed] [Google Scholar]
  30. Landin-Olsson M., Karlsson F. A., Lernmark A., Sundkvist G. Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. Diabetes. 1992 Aug;41(8):1022–1027. doi: 10.2337/diab.41.8.1022. [DOI] [PubMed] [Google Scholar]
  31. Lin R. H., Mamula M. J., Hardin J. A., Janeway C. A., Jr Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med. 1991 Jun 1;173(6):1433–1439. doi: 10.1084/jem.173.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lisker-Melman M., Di Bisceglie A. M., Usala S. J., Weintraub B., Murray L. M., Hoofnagle J. H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992 Jun;102(6):2155–2160. doi: 10.1016/0016-5085(92)90348-3. [DOI] [PubMed] [Google Scholar]
  33. Lopes E. P., Oliveira P. M., Silva A. E., Ferraz M. L., Costa C. H., Miranda W., Dib S. A. Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B. Lancet. 1994 Jan 22;343(8891):244–244. doi: 10.1016/s0140-6736(94)91035-9. [DOI] [PubMed] [Google Scholar]
  34. Maggiore G., Bernard O., Homberg J. C., Hadchouel M., Alvarez F., Hadchouel P., Odièvre M., Alagille D. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr. 1986 Mar;108(3):399–404. doi: 10.1016/s0022-3476(86)80880-0. [DOI] [PubMed] [Google Scholar]
  35. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Büschenfelde K. H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987 Feb 7;1(8528):292–294. doi: 10.1016/s0140-6736(87)92024-1. [DOI] [PubMed] [Google Scholar]
  36. Marcellin P., Pouteau M., Benhamou J. P. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995 Mar;22(3):364–369. doi: 10.1016/0168-8278(95)80291-6. [DOI] [PubMed] [Google Scholar]
  37. Mason A. L., Lau J. Y., Hoang N., Qian K., Alexander G. J., Xu L., Guo L., Jacob S., Regenstein F. G., Zimmerman R. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999 Feb;29(2):328–333. doi: 10.1002/hep.510290235. [DOI] [PubMed] [Google Scholar]
  38. Mayet W. J., Hess G., Gerken G., Rossol S., Voth R., Manns M., Meyer zum Büschenfelde K. H. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 1989 Jul;10(1):24–28. doi: 10.1002/hep.1840100106. [DOI] [PubMed] [Google Scholar]
  39. Michitaka K., Durazzo M., Tillmann H. L., Walker D., Philipp T., Manns M. P. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology. 1994 Jun;106(6):1603–1610. doi: 10.1016/0016-5085(94)90417-0. [DOI] [PubMed] [Google Scholar]
  40. Nduwayo L., Bacq Y., Valat C., Goudeau A., Lecomte P. Fonction et auto-immunité thyroïdienne chez 215 patients séropositifs pour le virus de l'hépatite C. Ann Endocrinol (Paris) 1998 Apr;59(1):9–13. [PubMed] [Google Scholar]
  41. Niskanen L. K., Tuomi T., Karjalainen J., Groop L. C., Uusitupa M. I. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995 Dec;18(12):1557–1565. doi: 10.2337/diacare.18.12.1557. [DOI] [PubMed] [Google Scholar]
  42. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996 Sep;25(3):283–291. doi: 10.1016/s0168-8278(96)80113-9. [DOI] [PubMed] [Google Scholar]
  43. Pawlotsky J. M., Ben Yahia M., Andre C., Voisin M. C., Intrator L., Roudot-Thoraval F., Deforges L., Duvoux C., Zafrani E. S., Duval J. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994 Apr;19(4):841–848. [PubMed] [Google Scholar]
  44. Philipp T., Durazzo M., Trautwein C., Alex B., Straub P., Lamb J. G., Johnson E. F., Tukey R. H., Manns M. P. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994 Aug 27;344(8922):578–581. doi: 10.1016/s0140-6736(94)91966-6. [DOI] [PubMed] [Google Scholar]
  45. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A. J., Houghton M., Rosa D., Grandi G. Binding of hepatitis C virus to CD81. Science. 1998 Oct 30;282(5390):938–941. doi: 10.1126/science.282.5390.938. [DOI] [PubMed] [Google Scholar]
  46. Powell M., Prentice L., Asawa T., Kato R., Sawicka J., Tanaka H., Petersen V., Munkley A., Morgan S., Rees Smith B. Glutamic acid decarboxylase autoantibody assay using 125I-labelled recombinant GAD65 produced in yeast. Clin Chim Acta. 1996 Dec 30;256(2):175–188. doi: 10.1016/s0009-8981(96)06422-4. [DOI] [PubMed] [Google Scholar]
  47. Schultz M., Müller R., von zur Mühlen A., Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet. 1989 Jun 24;1(8652):1452–1452. doi: 10.1016/s0140-6736(89)90157-8. [DOI] [PubMed] [Google Scholar]
  48. Seissler J., Morgenthaler N. G., Achenbach P., Lampeter E. F., Glawe D., Payton M., Christie M., Scherbaum W. A. Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie. Diabetologia. 1996 Nov;39(11):1351–1356. doi: 10.1007/s001250050582. [DOI] [PubMed] [Google Scholar]
  49. Su L., David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol. 1999 Jun 1;162(11):6317–6321. [PubMed] [Google Scholar]
  50. Tran A., Quaranta J. F., Benzaken S., Thiers V., Chau H. T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J. L. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993 Aug;18(2):253–257. [PubMed] [Google Scholar]
  51. Tuomi T., Carlsson A., Li H., Isomaa B., Miettinen A., Nilsson A., Nissén M., Ehrnström B. O., Forsén B., Snickars B. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999 Jan;48(1):150–157. doi: 10.2337/diabetes.48.1.150. [DOI] [PubMed] [Google Scholar]
  52. Vandewalle C. L., Falorni A., Svanholm S., Lernmark A., Pipeleers D. G., Gorus F. K. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab. 1995 Mar;80(3):846–851. doi: 10.1210/jcem.80.3.7883841. [DOI] [PubMed] [Google Scholar]
  53. Verge C. F., Stenger D., Bonifacio E., Colman P. G., Pilcher C., Bingley P. J., Eisenbarth G. S. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes. 1998 Dec;47(12):1857–1866. doi: 10.2337/diabetes.47.12.1857. [DOI] [PubMed] [Google Scholar]
  54. Wiest-Ladenburger U., Hartmann R., Hartmann U., Berling K., Böhm B. O., Richter W. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes. 1997 Apr;46(4):565–571. doi: 10.2337/diab.46.4.565. [DOI] [PubMed] [Google Scholar]
  55. Yoon J. W., Yoon C. S., Lim H. W., Huang Q. Q., Kang Y., Pyun K. H., Hirasawa K., Sherwin R. S., Jun H. S. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science. 1999 May 14;284(5417):1183–1187. doi: 10.1126/science.284.5417.1183. [DOI] [PubMed] [Google Scholar]
  56. di Cesare E., Previti M., Russo F., Brancatelli S., Ingemi M. C., Scoglio R., Mazzù N., Cucinotta D., Raimondo G. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci. 1996 Aug;41(8):1672–1677. doi: 10.1007/BF02087923. [DOI] [PubMed] [Google Scholar]
  57. von Boehmer H., Sarukhan A. GAD, a single autoantigen for diabetes. Science. 1999 May 14;284(5417):1135–1137. doi: 10.1126/science.284.5417.1135. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES